Intra-Cellular Therapies announces positive topline results in phase 3 trial evaluating Caplyta for the prevention of relapse in patients with schizophrenia
- Intra-Cellular Therapies reported positive results from a Phase 3 trial (Study 304) of lumateperone (Caplyta) for preventing relapse in schizophrenia.
- The trial showed a statistically significant longer time to relapse for patients on lumateperone compared to placebo, with a 63% reduction in relapse risk.
- The study was a 47-week, multicenter, double-blind, placebo-controlled trial involving 228 patients, with lumateperone showing favorable safety and tolerability.
- Next steps include potential regulatory submissions based on these findings.
Read more
Kite to highlight industry-leading CAR T-cell therapy portfolio at ASH 2024
- Kite will present 18 studies at the ASH 2024, showcasing its CAR T-cell therapy portfolio for blood cancers.
- Key data includes a 30.2-month median progression-free survival from a Phase 1 study of anito-cel for multiple myeloma.
- Yescarta shows superior overall survival in large B-cell lymphoma, with a five-year follow-up from the ZUMA-5 trial.
- Tecartus demonstrates durable responses in mantle cell lymphoma, with five-year outcomes from ZUMA-2 cohorts.
Read more
